VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

H.R. 1496 · 110th Congress

Beating Infections through Research and Development Act of 2007

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 110th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

BBD BairdSponsor
4 cosponsors · 1 D, 3 R

2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

Beating Infections through Research and Development Act of 2007 - Sets forth circumstances under which the term of a patent may be extended for qualified infectious disease products.

What it does: CRS summary · Introduced in House · Mar 13, 2007

Beating Infections through Research and Development Act of 2007 - Sets forth circumstances under which the term of a patent may be extended for qualified infectious disease products.

Requires the Secretary of Health and Human Services to designate qualified infectious disease products as fast-track products for approval.

Amends the Public Health Service Act to require the Director of the National Institute of Allergy and Infectious Diseases to expand and intensify efforts to assist small manufacturers to conduct end-stage clinical trials on qualified infectious disease products.

Amends the Internal Revenue Code to establish an infectious disease research credit and a qualified infectious disease products manufacturing facilities investment credit.

Establishes the Commission on Infectious Diseases Product Development to identify drug-resistant infectious pathogens that are a significant threat to public health and make recommendations to the Secretary on how best to address such pathogens.

Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary, acting through the Commissioner of Food and Drugs, to issue guidelines for the conduct of clinical trials with respect to antibiotic drugs.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Beating Infections through Research and Development Act of 2007

Latest action (Apr 20, 2007): Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.

Policy area: Health · Origin: House · Introduced: Mar 13, 2007

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.